<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017173</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068658</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0011</secondary_id>
    <nct_id>NCT00017173</nct_id>
  </id_info>
  <brief_title>S0011, Gene Therapy &amp; Surgery Followed by Chemo &amp; RT in Newly Diagnosed Cancer of the Mouth or Throat</brief_title>
  <official_title>Phase II Trial Of Surgery With Perioperative RPR/INGN 201 (Ad5CMV-p53) Gene Therapy Followed By Chemoradiotherapy For Advanced, Resectable Squamous Cell Carcinoma Of The Oral Cavity, Oropharynx, Larynx, and Pharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability&#xD;
      to fight cancer. Drugs used in chemotherapy use different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage&#xD;
      tumor cells. Combining chemotherapy and radiation therapy with the p53 gene may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of gene therapy plus surgery followed by&#xD;
      cisplatin and radiation therapy in treating patients who have newly diagnosed resectable&#xD;
      stage III or stage IV cancer of the mouth or throat.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of treating patients with newly diagnosed resectable stage III&#xD;
           or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx&#xD;
           with surgery and Ad5CMV-p53 gene followed by cisplatin and radiotherapy.&#xD;
&#xD;
        -  Determine the progression-free survival, local control, and overall survival of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo surgical resection and receive an intraoperative Ad5CMV-p53 gene injection&#xD;
      into the resection bed and into the deep soft tissue bed of the cervical level with nodal&#xD;
      metastasis. Patients also receive a third intraoperative Ad5CMV-p53 gene injection into the&#xD;
      neck dissection bed, where it is allowed to sit in place for 10 minutes.&#xD;
&#xD;
      Within 48-72 hours after surgery, patients receive a postoperative Ad5CMV-p53 gene injection&#xD;
      into each of two drainage catheters next to the mucosal suture line and neck dissection bed,&#xD;
      where it is allowed to sit in place for 2 hours.&#xD;
&#xD;
      Within 56 days after surgery, patients receive cisplatin IV over 30-90 minutes on days 1, 22,&#xD;
      and 43 and radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients may&#xD;
      receive 3 additional days of radiotherapy to high-risk areas on days 43-45.&#xD;
&#xD;
      Patients are followed every 2-6 months for 2 years and then annually for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for poor accrual.&#xD;
  </why_stopped>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>1 year</time_frame>
    <description>accrual rate and percentage of patients successfully receiving the required doses of INGN 201</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival from time of registration until disease progression</measure>
    <time_frame>two years</time_frame>
    <description>percentage of patient who have not experience progression of disease at two years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>surgery with INGN 201 followed by chemo/RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5CMV-p53 gene</intervention_name>
    <description>2 intraoperative and one post-operative injection of Ad5CMV-p53.</description>
    <arm_group_label>surgery with INGN 201 followed by chemo/RT</arm_group_label>
    <other_name>INGN 201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>100 mg/m2 IV Day 1 every 21 days for 3 cycles</description>
    <arm_group_label>surgery with INGN 201 followed by chemo/RT</arm_group_label>
    <other_name>platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>conventional surgery</description>
    <arm_group_label>surgery with INGN 201 followed by chemo/RT</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>200 cGy per day Days 105 every week for 6 weeks</description>
    <arm_group_label>surgery with INGN 201 followed by chemo/RT</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-risk/limited stage III or IV squamous cell carcinoma of&#xD;
             the oral cavity, oropharynx, hypopharynx, and larynx&#xD;
&#xD;
               -  Newly diagnosed&#xD;
&#xD;
               -  Previously untreated&#xD;
&#xD;
               -  Considered surgically resectable&#xD;
&#xD;
               -  Evidence of regional lymph node metastases (N1-N3)&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 3 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Magnesium normal (magnesium supplement allowed)&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer in complete remission&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Patients must use effective barrier contraception and prevent bodily fluid&#xD;
             transmission during and for 28 days after Ad5CMV-p53 gene administration&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent intensity-modulated radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George H. Yoo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markey Cancer Center at University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

